RANCHO SANTA MARGARITA, Calif., May 01, 2018 -- Melissa, a leading provider of global contact data quality and identity verification solutions, today announced Druginator, a new, tightly targeted element of its comprehensive data quality toolset to clean, harmonize, and connect disparate content sources for clinical insight and discovery. As part of the Melissa Informatics array of data quality solutions, datasets, and knowledge engineering resources, Druginator checks and validates millions of pharmaceutical drug names, variants, dosages, and spellings in real-time, against a comprehensive drug lexicon aligned with industry standards. The Melissa Informatics team will feature Druginator at the Bio-IT World Conference and Expo, #BioIT18, booth M634, May 15-17, 2018, at the Seaport World Trade Center in Boston.
Druginator provides a web-based UI for checking, verifying, and enriching drug names or lists of drugs, as well as web service APIs for drug data. Diverse, misspelled, and otherwise “dirty” drug information, whether from electronic medical records (EMRs) or from pharmaceutical dictionaries, studies, or public sources, is checked and reported with standardized “preferred terms” to become instantly usable for pharmaceutical and healthcare informatics. This provides an efficient resource to help researchers and clinicians check, verify, and normalize drug terms to reduce costs, increase accuracy, and improve research and patient outcomes.
Aligning with the industry goal to advance medicine through optimized data, Druginator harnesses the power of formal semantic technologies to apply machine reasoning to infer new concepts, linkages, and corrections to data about drugs. Future versions of Druginator will harmonize other types of mission-critical clinical data, such as diseases, genes, and proteins.
“Disconnected data is messy and not contextualized, slowing mission-critical goals such as FDA approval, time to market and understanding real-world use patterns for drugs. For example, a single medical records database was shown to contain nearly 200 different variations, spellings, and compounds of just one drug commonly used in the treatment of Parkinson’s disease. Discrepancies like this can have crucial implications on patient analyses, treatments, and treatment outcomes,” said Daniel Kha Le, vice president, Melissa Informatics.
Melissa Informatics’ drug, patient, disease, gene, protein, metabolic, and consumer-centered ontologies allow clinicians to easily refocus their research, tapping into different contextual insights based on the same data sets. With Druginator, drug names are checked and verified against a database of drug standard names, to meet FDA, UMLS and other terminology standards as required. Druginator’s append feature searches variations, alternate names, combination drugs, and available dosages to deliver comprehensive intelligence about your checked and verified drug. Autocompletion capabilities accelerate data entry, ensure standardization, and reduce clerical errors by offering an auto-populated list of variants matched in real-time.
Druginator is part of Melissa Informatics’ Sentient™ platform – semantic technologies that can be applied horizontally to accommodate the broad spectrum of pharmaceutical and clinical data harmonization and enrichment needs, integrating content across virtually any data format or terminology regardless of its original source. To connect with Melissa Informatics or members of Melissa’s global intelligence team, visit www.Melissa.com or call 1-800-MELISSA.
About Melissa
Since 1985, Melissa has specialized in global intelligence solutions to help organizations unlock accurate data for a more compelling customer view. More than 10,000 clients worldwide in arenas such as retail, education, healthcare, insurance, finance, and government, rely on Melissa for full spectrum data quality and ID verification software, including data matching, validation, and enhancement services to gain critical insight and drive meaningful customer relationships. For more information or free product trials, visit www.Melissa.com or call 1-800-MELISSA (635-4772).
About Melissa Informatics
Melissa Informatics extends the capabilities of Melissa’s global intelligence software and services to support world leaders in life sciences, biotechnology, pharmaceutical, and medical industries by harnessing the entire data lifecycle for business, pharmaceutical and clinical data. Our software and services bring data quality and machine reasoning together for insight and discovery by intelligently cleaning, connecting, and harmonizing multiple sources to offer interoperable data. Melissa Informatics reduces time and cost to benefit from clean, richly connected data. Revealing deeper data relationships from complex, dynamic data through machine reasoning operations, Melissa Informatics ensures the most reliable information in mission critical financial services, healthcare, and life science informatics. For more information or free product trials, visit www.Melissa.com/informatics or call 1-800-MELISSA (635-4772).
| Greg Brown | Jackie Zerbst | ||||
| Vice President, Marketing | MPowered Public Relations | ||||
| Melissa | [email protected] | ||||
| [email protected] | (714) 998-3448 | ||||
| (800) 635-4772 x1130 |


Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails
Freedom Finance and Binance Join Forces in Digital Assets
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16%
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 



